Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease
- PMID: 40803819
- PMCID: PMC12352244
- DOI: 10.1136/rmdopen-2025-005754
Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease
Abstract
Objective: The common gain-of-function variant rs35705950, located in the promoter of MUC5B gene, has been strongly associated with interstitial lung diseases (ILDs) of different aetiology, such as idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis-associated ILD (RA-ILD). In this study, we aimed to investigate the association of this variant and its nearby single nucleotide polymorphisms (SNPs) in the largest cohort of systemic sclerosis-associated ILD (SSc-ILD) to date.
Methods: Samples were collected from blood/saliva, followed by DNA extraction and genotyping using SNP arrays. Data for rs35705950 and additional 903 variants within 100 Kb were obtained using genomic imputation. Subsequently, we tested their association in a meta-analysis to increase the consistency of the results, including 10 European ancestry cohorts comprising 2363 patients with SSc-ILD, 3526 SSc patients without ILD and 15 076 controls.
Results: Meta-analysis showed no significant association between rs35705950 and SSc-ILD, either comparing patients with SSc with and without ILD (p value: 0.588, OR: 1.05, 95% CI: 0.87 to 1.27) nor patients with SSc-ILD with controls (p value: 0.061, OR: 1.16, 95% CI: 0.99 to 1.36). Moreover, none of the additional 903 variants tested in the genomic region reached statistical significance.
Conclusion: Despite analysing the largest and most statistically powered SSc-ILD cohort to date, we found no evidence of association between the MUC5B promoter variant rs35705950 and its surrounding SNPs with SSc-ILD. These results suggest that the pathogenic mechanisms underlying SSc-ILD may only partially overlap with those of other similar ILDs, such as IPF or RA-ILD. This highlights the need for further studies regarding their genetic architecture.
Keywords: Lung Diseases, Interstitial; Polymorphism, Genetic; Scleroderma, Systemic.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: SMP has received honoraria from Janssen, Boehringer Ingelheim, MSD. MN has received honoraria or consultancies from Janssen, AstraZeneca, GlaxoSmithKlein, Boehringer Ingelheim and Bristol Myers Squibb. The Australian Scleroderma Cohort Study (ASCS) is supported by Janssen, Boehringer Ingelheim, Scleroderma Australia, Scleroderma Victoria, Arthritis Australia, Musculoskeletal Australia (muscle, bone and joint health), Australian Rheumatology Association and St Vincent’s Hospital Melbourne IT Department and Research Endowment Fund (REF).
Figures

Similar articles
-
FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease.Rheumatology (Oxford). 2024 Oct 17:keae573. doi: 10.1093/rheumatology/keae573. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 39418199
-
Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis.Mol Med. 2025 Feb 20;31(1):70. doi: 10.1186/s10020-025-01128-2. Mol Med. 2025. PMID: 39979794 Free PMC article.
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251336896. doi: 10.1177/17534666251336896. Epub 2025 May 8. Ther Adv Respir Dis. 2025. PMID: 40337907 Free PMC article.
-
Associations between genetic variants of Toll-interacting proteins and interstitial lung diseases: a systematic review and meta-analysis.Orphanet J Rare Dis. 2024 Nov 22;19(1):432. doi: 10.1186/s13023-024-03410-8. Orphanet J Rare Dis. 2024. PMID: 39578840 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical